Cited by 374Cancer Cells and MetastasisCell Adhesion Molecules ResearchProtein Kinase Regulation and GTPase Signaling

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition

Open access

Seguin, Laetitia, Kato, Shumei, Franovic, Aleksandra, Camargo, M. Fernanda, Lesperance, Jacqueline, Elliott, Kathryn C., Yebra, Mayra, Mielgo, Ainhoa, Lowy, Andrew M., Husain, Hatim, Cascone, Tina, Diao, Lixia, Wang, Jing, Wistuba, Ignacio I., Heymach, John V., Lippman, Scott M., Desgrosellier, Jay S., Anand, Sudarshan, Weis, Sara M., Cheresh, David A.·2014·Nature Cell Biology

DOI 10.1038/ncb2953PMC PMC4105198

Open this paper in CoChat — free account

Abstract

Tumour cells, with stem-like properties, are highly aggressive and often show drug resistance. Here, we reveal that integrin α(v)β₃ serves as a marker of breast, lung and pancreatic carcinomas with stem-like properties that are highly resistant to receptor tyrosine kinase inhibitors such as erlotinib. This was observed in vitro and in mice bearing patient-derived tumour xenografts or in clinical specimens from lung cancer patients who had progressed on erlotinib. Mechanistically, α(v)β₃, in the unliganded state, recruits KRAS and RalB to the tumour cell plasma membrane, leading to the activation of TBK1 and NF-κB. In fact, α(v)β₃ expression and the resulting KRAS-RalB-NF-κB pathway were both necessary and sufficient for tumour initiation, anchorage independence, self-renewal and erlotinib resistance. Pharmacological targeting of this pathway with bortezomib reversed both tumour stemness and erlotinib resistance. These findings not only identify α(v)β₃ as a marker/driver of carcinoma stemness but also reveal a therapeutic strategy to sensitize such tumours to RTK inhibition.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/ncb2953

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2748 · Cited by 3,815
Self-citation
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2499 · Cited by 3,501
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Self-citation
Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer
Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M. O., Bruns, C. J., & Heeschen, C. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.06.002 · Cited by 2,946
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,095
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789

Flagged first, then by citations

Show all 59 references

Sorted by citations

Items 201–300 of 374

Osteopontin drives KRAS-mutant lung adenocarcinoma
Giopanou, I., Kanellakis, N. I., Giannou, A. D., Lilis, I., Marazioti, A., Σπέλλα, Μ., Papaleonidopoulos, V., Simoes, D. C. M., Zazara, D. E., Agalioti, T., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz190 · Cited by 22
Integrin αvβ3 Upregulation in Response to Nutrient Stress Promotes Lung Cancer Cell Metabolic Plasticity
Nam, A., Jain, S., Wu, C., Campos, A. D., Shepard, R. M., Yu, Z., Reddy, J. P., Schalscha, T. V., Weis, S. M., Onaitis, M. W., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2700 · Cited by 21
Self-citation
FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
Bernat‐Peguera, A., Navarro-Ventura, J., Lorenzo-Sanz, L., da Silva-Diz, V., Bosio, M., Palomero, L., Penin, R. M., Sidelnikova, D. P., Bermejo, J. O., Taberna, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0232 · Cited by 21
Ligand-independent integrin β1 signaling supports lung adenocarcinoma development
Haake, S. M., Plosa, E. J., Kropski, J. A., Venton, L., Reddy, A., Bock, F. M., Chang, B. T., Luna, A. J., Nabukhotna, K., Xu, Z., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.154098 · Cited by 20
Biochemical and biomechanical drivers of cancer cell metastasis, drug response and nanomedicine
Yoshii, T., Geng, Y., Peyton, S. R., Mercurio, A. M., & Rotello, V. M. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.011 · Cited by 20
Three-dimensional hydrogel is suitable for targeted investigation of amoeboid migration of glioma cells
Huang, Y., Tong, L., Li, Y., Zhang, C., Hai, L., Li, T., Yu, S., Wang, W., Tao, Z., Ma, H., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7888 · Cited by 21
Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
Das, T. K., Esernio, J., & Cagan, R. L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2001 · Cited by 21
Clinical update on K-Ras targeted therapy in gastrointestinal cancers
Pant, S., Hubbard, J. M., Martinelli, E., & Bekaii‐Saab, T. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.011 · Cited by 21
Chemosensitizing activity of peptide from Lentinus squarrosulus (Mont.) on cisplatin-induced apoptosis in human lung cancer cells
Khine, H. E. E., Ecoy, G. A. U., Roytrakul, S., Phaonakrop, N., Pornputtapong, N., Prompetchara, E., Pithi Chanvorachote, B., & Chaotham, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-83606-1 · Cited by 20
ITGB3 promotes cisplatin resistance in osteosarcoma tumors
Li, Q., Chen, G., Jiang, H., Dai, H., Li, D., Zhu, K., Zhang, K., Shen, H., Xu, H., & Li, S. (2023) · Cancer Medicine · doi:10.1002/cam4.5585 · Cited by 19
tRNA modifications and tRNA-derived small RNAs: new insights of tRNA in human disease
Wu, D., Li, X., Khan, F. A., Yuan, C., Pandupuspitasari, N. S., Huang, C., Sun, F., & Guan, K. (2024) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09919-9 · Cited by 24
The innate immune signaling in cancer and cardiometabolic diseases: Friends or foes?
Wang, W., Zhang, Y., Yang, L., & Li, H. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.004 · Cited by 21
‘Normalizing’ the malignant phenotype of luminal breast cancer cells via alpha(v)beta(3)-integrin
Abu-Tayeh, H., Weidenfeld, K., Zhilin-Roth, A., Schif‐Zuck, S., Thaler, S., Cotarelo, C., Tan, T. Z., Thiery, J. P., Green, J. E., Klorin, G., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.387 · Cited by 20
RETRACTED: Upregulation of FoxM1 by MnSOD Overexpression Contributes to Cancer Stem-Like Cell Characteristics in the Lung Cancer H460 Cell Line
Fu, Z., Cao, X., Yang, Y., Song, Z., Zhang, J., & Wang, Z. (2018) · Technology in Cancer Research & Treatment · doi:10.1177/1533033818789635 · Cited by 20
Retracted
NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors
Park, H.-R., Ahn, Y., Kim, T. M., Kim, S., Kim, S., LEE, Y. S., KIM, M., Keam, B., Kim, D.-W., & Heo, D. S. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.03.312 · Cited by 20
Targeting macropinocytosis for cancer therapy
Tang, D., Wang, J., Kroemer, G., & Kang, R. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00892-x · Cited by 26
Self-citation
LINC01798/miR-17-5p axis regulates ITGA8 and causes changes in tumor microenvironment and stemness in lung adenocarcinoma
Li, X., Zhu, G., Li, Y., Huang, H., Wu, D., 曹佩军, Shi, R., Chen, C., Su, L., Zhang, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1096818 · Cited by 18
[99mTc][Tc(N)PNP43]-Labeled RGD Peptides As New Probes for a Selective Detection of αvβ3 Integrin: Synthesis, Structure–Activity and Pharmacokinetic Studies
Bolzati, C., Salvarese, N., Carpanese, D., Seraglia, R., Meléndez‐Alafort, L., Rosato, A., Capasso, D., Saviano, M., Gatto, A. D., Comegna, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01075 · Cited by 19
Integrin β8 facilitates tumor growth and drug resistance through a Y‐box binding protein 1‐dependent signaling pathway in bladder cancer
Liu, S., Chen, L., Zhao, H., Li, Q., Hu, R., & Wang, H. (2020) · Cancer Science · doi:10.1111/cas.14439 · Cited by 19
Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy
Er, A. B. B., Sheldrake, H. M., & Sutherland, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147946 · Cited by 18
Targeting Pancreatic Cancer Cell Stemness by Blocking Fibronectin-Binding Integrins on Cancer-Associated Fibroblasts
Wu, C., Schalscha, T. V., Sansanwal, D., Qian, C., Jiang, Q., Shepard, R. M., Wettersten, H. I., McCormack, S. J., Weis, S. M., & Cheresh, D. A. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0491 · Cited by 18
Self-citation
Reprogramming the tumor metastasis cascade by targeting galectin-driven networks
Perrotta, R. M., Bach, C. A., Salatino, M., & Rabinovich, G. A. (2021) · Biochemical Journal · doi:10.1042/bcj20200167 · Cited by 18
Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway
Sun, Q., Lü, Z., Zhang, Y., Xue, D., Xia, H., She, J., & Li, F. (2022) · Cells · doi:10.3390/cells11132078 · Cited by 18
The Role of Molecular and Hormonal Factors in Obesity and the Effects of Physical Activity in Children
Aragón‐Vela, J., Carrillo, J. A.-B., Moreno-Racero, A., & Plaza‐Díaz, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315413 · Cited by 19
Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting
Michael, J. V., & Goldfinger, L. E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.021 · Cited by 18
Blockade of integrin β3 signals to reverse the stem-like phenotype and drug resistance in melanoma
Zhu, X., Tao, X., Lü, W., Ding, Y., & Tang, Y. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3760-z · Cited by 18
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer
Khawaja, H. A., Campbell, A. D., Roberts, J. Z., Javadi, A., O’Reilly, P. G., McArt, D. G., Allen, W. L., Majkut, J., Rehm, M., Bardelli, A., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03131-3 · Cited by 18
Autoregulation of insulin receptor signaling through MFGE8 and the αvβ5 integrin
Datta, R., Lizama, C. O., Soltani, A. K., McKleroy, W., Podolsky, M. J., Yang, C. D., Huynh, T. L., Cautivo, K. M., Wang, B., Koliwad, S. K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102171118 · Cited by 18
Upregulation of fibronectin and its integrin receptors – an adaptation to isolation stress that facilitates tumor initiation
Wu, C., Weis, S. M., & Cheresh, D. A. (2023) · Journal of Cell Science · doi:10.1242/jcs.261483 · Cited by 18
Self-citation
Early-stage lung cancer is driven by a transitional cell state dependent on a KRAS-ITGA3-SRC axis
Moye, A. L., Dost, A. F. M., Ietswaart, R., Sengupta, S., Ya, V., Aluya, C., Fahey, C. G., Louie, S. M., Paschini, M., & Kim, C. F. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00113-5 · Cited by 18
Tension in Cancer
Löffek, S., Franzke, C.-W., & Helfrich, I. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111910 · Cited by 18
Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies
Kato, S., Okamura, R., Sicklick, J., Daniels, G., Hong, D., Goodman, A., Weihe, E., Lee, S., Khalid, N., Collier, R., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32813 · Cited by 16
Self-citation
PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin β3-KRAS-dependent pancreatic cancer stem cells
Cheng, J., & Cashman, J. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-65804-5 · Cited by 17
A STAT3/integrin axis accelerates pancreatic cancer initiation and progression
Campos, A. D., Shepard, R. M., Ortega, Z. M., Heumann, I., Wilke, A. E., Nam, A., Cable, C., Kouhmareh, K., Klemke, R., Mattson, N. M., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116010 · Cited by 16
Self-citation
Exposure to Bacteriophages T4 and M13 Increases Integrin Gene Expression and Impairs Migration of Human PC-3 Prostate Cancer Cells
Sanmukh, S. G., dos Santos, N. J., Barquilha, C. N., dos Santos, S. A. A., Duran, B. O. D. S., Delella, F. K., Moroz, A., Justulin, L. A., Carvalho, H. F., & Felisbino, S. L. (2021) · Antibiotics · doi:10.3390/antibiotics10101202 · Cited by 16
Integrin αvβ3 Is a Master Regulator of Resistance to TKI-Induced Ferroptosis in HER2-Positive Breast Cancer
Nagpal, A., Needham, K. A., Lane, D. J. R., Ayton, S., Redvers, R. P., John, M., Selistre-de-Araújo, H. S., Denoyer, D., & Pouliot, N. (2023) · Cancers · doi:10.3390/cancers15041216 · Cited by 16
Role of adhesion molecules in cancer and targeted therapy
Fan, C., Xiong, F., Zhang, S., Gong, Z., Liao, Q., Li, G., Guo, C. J., Xiong, W., Huang, H., & Zeng, Z. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2417-3 · Cited by 16
Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells
Stacer, A. C., Wang, H., Fenner, J., Dosch, J. S., Salomonnson, A., Luker, K. E., Luker, G. D., Rehemtulla, A., & Ross, B. D. (2015) · Molecular Imaging · doi:10.2310/7290.2015.00016 · Cited by 16
Role of Dietary Cancer-Preventive Phytochemicals in Pancreatic Cancer Stem Cells
Kumar, G., Farooqui, M., & Rao, C. V. (2018) · Current Pharmacology Reports · doi:10.1007/s40495-018-0145-2 · Cited by 15
Spatial activation of ezrin by epidermal growth factor receptor and focal adhesion kinase co-ordinates epithelial cell migration
Chan, G. K., McGrath, J. A., & Parsons, M. (2021) · Open Biology · doi:10.1098/rsob.210166 · Cited by 15
PKCδ regulates integrin αVβ3 expression and transformed growth of K-ras dependent lung cancer cells
Symonds, J. M., Ohm, A. M., Tan, A. C., & Reyland, M. E. (2016) · Oncotarget · doi:10.18632/oncotarget.7560 · Cited by 15
BRD1-Mediated Acetylation Promotes Integrin αV Gene Expression Via Interaction with Sulfatide
Cai, Q., Dong, Y. W., Qi, B., Shao, X., Wang, R., Chen, Z. Y., He, B. M., & Wu, X. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0527 · Cited by 15
Reversal of EGFR inhibitors’ resistance by co-delivering EGFR and integrin αvβ3 inhibitors with nanoparticles in non-small cell lung cancer
He, F., Wang, Y., Cai, W., Li, M., & Dong, L. (2019) · Bioscience Reports · doi:10.1042/bsr20181259 · Cited by 15
Targeting ITGβ3 to Overcome Trastuzumab Resistance through Epithelial–Mesenchymal Transition Regulation in HER2-Positive Breast Cancer
Er, A. B. B., & Er, İ. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168640 · Cited by 14
Tobacco chemical-induced mouse lung adenocarcinoma cell lines pin the prolactin orthologue proliferin as a lung tumour promoter
Kanellakis, N. I., Giannou, A. D., Pepe, M. A. A., Agalioti, T., Zazara, D. E., Giopanou, I., Psallidas, I., Σπέλλα, Μ., Marazioti, A., Arendt, K. A. M., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz047 · Cited by 12
Heparanase in Cancer Metastasis – Heparin as a Potential Inhibitor of Cell Adhesion Molecules
Bendas, G., & Borsig, L. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34521-1_11 · Cited by 14
Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner
Bontoux, C., Hofman, V., Brest, P., Ilié, M., Mograbi, B., & Hofman, P. M. (2022) · Cancers · doi:10.3390/cancers14071628 · Cited by 17
Tumor-initiating cells establish a niche to overcome isolation stress
Wu, C., Weis, S. M., & Cheresh, D. A. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.08.001 · Cited by 14
Self-citation
Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer
Shi, H., Tsang, Y., & Yang, Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-10397-7 · Cited by 16
Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer
Guo, D., Ye, L., Wu, W., Yu, X., & Jin, K. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023045 · Cited by 13
Protein‐Targeted Glycan Editing on Living Cells Disrupts KRAS Signaling
Li, Y., Huo, F., Chen, L., Wang, H., Wu, J., Zhang, P., Feng, N., Li, W., Wang, L., Wang, Y., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202218148 · Cited by 13
Functional proteomic analysis reveals roles for PKCδ in regulation of cell survival and cell death: Implications for cancer pathogenesis and therapy
Speidel, J. T., Affandi, T., Jones, D. N. M., Ferrara, S. E., & Reyland, M. E. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100757 · Cited by 13
TGFβ promotes YAP‐dependent AXL induction in mesenchymal‐type lung cancer cells
Choi, J., Lee, H., Kwon, E., Kong, H., Kwon, O., & Cha, H. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12857 · Cited by 13
Emerging Roles of Galectin-3 in Pulmonary Diseases
Jia, Q., Yang, Y., Yao, S., Chen, X., & Hu, Z. (2024) · Lung · doi:10.1007/s00408-024-00709-y · Cited by 12
Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery
Berman, M., Mattheolabakis, G., Suresh, M., & Amiji, M. M. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1178236 · Cited by 12
c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis
Leslie, J., Hunter, J. E., Collins, A., Rushton, A. J., Russell, L. G., Ramon‐Gil, E., Laszczewska, M., McCain, M. V., Zaki, M. Y. W., Knox, A., et al. (2022) · Hepatology · doi:10.1002/hep.32781 · Cited by 12
LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells
Lim, S.-Y., Macheleidt, I. F., Dalvi, P. S., Schäfer, S. C., Kerick, M., Ozretić, L., Ortiz‐Cuaran, S., George, J., Merkelbach‐Bruse, S., Wolf, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09554-x · Cited by 12
In situ validation of VEGFR-2 and α v ß 3 integrin as targets for breast lesion characterization
Ehling, J., Misiewicz, M., von Stillfried, S. F., Möckel, D., Bzyl, J., Pochon, S., Lederle, W., Knuechel, R., Lammers, T., Palmowski, M., et al. (2016) · Angiogenesis · doi:10.1007/s10456-016-9499-4 · Cited by 11
Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment
Sharma, S., Mann, A. P., Mölder, T., Kotamraju, V. R., Mattrey, R. F., Teesalu, T., & Ruoslahti, E. I. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.006 · Cited by 11
Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis
Desnoyers, A., González, C., Pérez‐Segura, P., Pandiella, A., Amir, E., & Ocaña, A. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00450-1 · Cited by 11
Targeting the IκB Kinase Enhancer and Its Feedback Circuit in Pancreatic Cancer
Challa, S., Husain, K. M., Kim, R., Coppola, D., Batra, S. K., Cheng, J. Q., & Malafa, M. P. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.11.009 · Cited by 10
Cancer stem-like cells stay in a plastic state ready for tumor evolution
Xu, J., Zhang, H., Nie, Z., He, W., Zhao, Y., Huang, Z., Jia, L., Du, Z., Zhang, B., & Xia, S. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101134 · Cited by 10
A Review of Talin- and Integrin-Dependent Molecular Mechanisms in Cancer Invasion and Metastasis
Baster, Z., Russell, L., & Rajfur, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051798 · Cited by 11
Integrins Within the Tumor Microenvironment: Biological Functions, Importance for Molecular Targeting, and Cancer Therapeutics Innovation
Dzobo, K. (2021) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2021.0069 · Cited by 9
Sulfatide interacts with and activates integrin αVβ3 in human hepatocellular carcinoma cells
Wang, R., Qi, B., Dong, Y. W., Cai, Q., Deng, N. H., Chen, Q., Li, C., Jin, Y. T., & Wu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9095 · Cited by 10
Differential Kras V12 protein levels control a switch regulating lung cancer cell morphology and motility
Schäfer, C., Mohan, A. S., Burford, W. B., Driscoll, M., Ludlow, A. T., Wright, W. E., Shay, J. W., & Danuser, G. M. (2016) · Convergent Science Physical Oncology · doi:10.1088/2057-1739/2/3/035004 · Cited by 10
Application of decoy oligodeoxynucleotides strategy for inhibition of cell growth and reduction of metastatic properties in nonresistant and erlotinib‐resistant SW480 cell line
Asadi, Z., Fathi, M., Rismani, E., Bigdelou, Z., & Johari, B. (2020) · Cell Biology International · doi:10.1002/cbin.11543 · Cited by 10
Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer
Samardzija, C., Luwor, R. B., Quinn, M. A., Kannourakis, G., Findlay, J. K., & Ahmed, N. (2016) · BMC Cancer · doi:10.1186/s12885-016-2458-z · Cited by 10
Inhibition of integrin β3, a binding partner of kallistatin, leads to reduced viability, invasion and proliferation in NCI-H446 cells
Wang, G., Wang, X., Huang, X., Yang, H., Pang, S.-Q., Xie, X., Zeng, S., Lin, J., & Diao, Y. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0365-7 · Cited by 10
Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer Therapy
Sutherland, M., Gordon, A. H., Alshammari, F. O. F. O., Throup, A., Corte, A. L. C. L., Philippou, H., Shnyder, S. D., Patterson, L. H., & Sheldrake, H. M. (2023) · Cancers · doi:10.3390/cancers15164023 · Cited by 9
TBK1 is paradoxical in tumor development: a focus on the pathway mediating IFN-I expression
Wang, B., Zhang, F., Wu, X., & Ji, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433321 · Cited by 9
The c-Rel-c-Myc axis controls metabolism and proliferation of human T leukemia cells
Li, X., Luo, G., Li, T., Sun, H., Wang, W., Eiler, E., Goldsmith, J. R., & Chen, Y. H. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.06.029 · Cited by 9
High beta integrin expression is differentially associated with worsened pancreatic ductal adenocarcinoma outcomes.
Benesch, M. G. K., Wu, R., Menon, G., & Takabe, K. (2022) · PubMed Central · Cited by 9
Ribosomal S6 protein kinase 4 promotes resistance to EZH2 inhibitors in glioblastoma
Pang, F., Zhang, L., Li, M., Yi, X., Wang, Y., Yang, P., Wen, B., Jiang, J., Teng, Y., Yang, X., et al. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00666-3 · Cited by 9
NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models
Li, H., Peyser, N. D., Zeng, Y., Ha, P. K., Johnson, D. E., & Grandis, J. R. (2022) · Cancers · doi:10.3390/cancers14030506 · Cited by 9
Modeling Epidermal Growth Factor Inhibitor‐mediated Enhancement of Photodynamic Therapy Efficacy Using 3D Mesothelioma Cell Culture
Cramer, G. M., Shin, M. H., Hagan, S., Katz, S. I., Simone, C. B., Busch, T. M., & Cengel, K. A. (2018) · Photochemistry and Photobiology · doi:10.1111/php.13067 · Cited by 9
Galectin-3 Release in the Bone Marrow Microenvironment Promotes Drug Resistance and Relapse in Acute Myeloid Leukemia
Yıldırım, C. (2025) · Life · doi:10.3390/life15060937 · Cited by 8
A novel focal adhesion related gene signature for prognostic prediction in hepatocellular carcinoma
Lin, Z., Miao, D., Qian, X., Wang, X., & Yu, F. (2021) · Aging · doi:10.18632/aging.202871 · Cited by 8
MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels
Närvä, E., Taskinen, M. E., Lilla, S., Isomursu, A., Pietilä, M., Weltner, J., Isola, J. J., Sihto, H. J., Joensuu, H., Zanivan, S. R., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104459 · Cited by 8
Heat-Shock Protein 90-Targeted Nano Anticancer Therapy.
Rochani, A. K., Girija, A. R., Borah, A., Maekawa, T., & Kumar, D. S. (2016) · Journal of Pharmacy and Science · doi:10.1016/j.xphs.2015.10.007 · Cited by 8
Novel omics technology driving translational research in precision oncology
Basu, A., Budhraja, A., Juwayria, Abhilash, D., & Gupta, I. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.003 · Cited by 7
RETRACTED: Triazole Modified Tetraiodothyroacetic Acid Conjugated to Polyethylene Glycol, a Thyrointegrin αvβ3 Antagonist as a Radio- and Chemo-Sensitizer in Pancreatic Cancer
Sudha, T., Godugu, K., Glinsky, G. V., & Mousa, S. A. (2022) · Biomedicines · doi:10.3390/biomedicines10040795 · Cited by 7
Retracted
TGFβ1/integrin β3 positive feedback loop contributes to acquired EGFR TKI resistance in EGFR-mutant lung cancer
Wang, T., Zhang, Y., Cheng, H., Li, L., & Xu, L. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2064480 · Cited by 7
Integrin αvβ3 and RGD-based radiopharmaceuticals
Withofs, N., & Hustinx, R. (2016) · Médecine Nucléaire · doi:10.1016/j.mednuc.2015.12.002 · Cited by 7
Reversing microtubule‐directed chemotherapeutic drug resistance by co‐delivering α2β1 inhibitor and paclitaxel with nanoparticles in ovarian cancer
Zheng, W., Ge, D., & Meng, G. (2019) · Cell Biology International · doi:10.1002/cbin.11261 · Cited by 7
The role of ral signaling and post translational modifications (PTMs) of Ras in cancer
Zinatizadeh, M. R., Zarandi, P. K., Keshavarz‐Fathi, M., Yousefi, M. H., & Rezaei, N. (2022) · Genome Instability & Disease · doi:10.1007/s42764-022-00059-0 · Cited by 6
High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes
Rinaldetti, S. L., Zhou, Q., Abbott, J. M., de Jong, F. C., Esquer, H., Costello, J. C., Theodorescu, D., & LaBarbera, D. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810605 · Cited by 7
Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance
Río-Vilariño, A., del Puerto‐Nevado, L., García‐Foncillas, J., & Cebrián, A. (2021) · Cancers · doi:10.3390/cancers13153757 · Cited by 6
Non-Oncogene Addiction of KRAS-Mutant Cancers to IL-1β via Versican and Mononuclear IKKβ
Σπέλλα, Μ., Ntaliarda, G., Skiadas, G., Lamort, A., Vreka, M., Marazioti, A., Lilis, I., Bouloukou, E., Giotopoulou, G. A., Pepe, M. A. A., et al. (2023) · Cancers · doi:10.3390/cancers15061866 · Cited by 6
Integrin-mediated resistance to epidermal growth factor receptor-targeted therapy: an inflammatory situation
Brown, W. S., & Wendt, M. K. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0448-0 · Cited by 6
Single-Cell Proteomic Profiling Identifies Nanoparticle Enhanced Therapy for Triple Negative Breast Cancer Stem Cells
Wang, W., Lei, B., Li, L., Liu, J., Li, Z., Pang, Y., Liu, T., & Li, Z. (2021) · Cells · doi:10.3390/cells10112842 · Cited by 6
c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT
Bakırdöğen, D., Görgülü, K., Xin, J., Richter, L., Alcalá, S., Ruíz-Cañas, L., Dai, C., Frank, K. J., Wu, N., Diakopoulos, K. N., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02486-5 · Cited by 5
IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells
Rodrigues, F. S., Miranda, V. S., Carneiro-Lobo, T., Scalabrini, L. C., Kruspig, B., Levantini, E., Murphy, D. J., & Bassères, D. S. D. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165806 · Cited by 5
Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
Lu, S., Pan, X., Volckova, E., Shinde, A., Fuller, S. R., Egan, R. K., Ma, J., Kung, J., Ott, C. J., Hata, A. N., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0213 · Cited by 5
A stumbling block in pancreatic cancer treatment: drug resistance signaling networks
Liu, J., Zhang, B., Huang, B., Zhang, K., Guo, F., Wang, Z., & Shang, D. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1462808 · Cited by 5
PAWI-2: A novel inhibitor for eradication of cancer
Cheng, J., & Cashman, J. R. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02575-8 · Cited by 5
Mechanisms and Markers of Clinical Radioresistance
Binkley, M. S., Diehn, M., Eke, I., & Willers, H. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_4 · Cited by 6
Calcitriol Suppressed Isoproterenol-induced Proliferation of Cardiac Fibroblasts via Integrin β3/FAK/Akt Pathway
Wang, X.-F., Li, Q., Sun, X., Zheng, L., Cheng, S., & Zhu, Y. (2023) · Current Medical Science · doi:10.1007/s11596-022-2681-6 · Cited by 5
A link between RelB expression and tumor progression in laryngeal cancer
Giopanou, I., Lilis, I., Papadaki, H. H., Papadas, T. A., & Stathopoulos, G. T. (2017) · Oncotarget · doi:10.18632/oncotarget.23109 · Cited by 6
Ribonucleic acid (RNA) biosynthesis in human cancer
Hajjawi, O. S. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0167-3 · Cited by 5

Authors: Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Lesperance, J., Elliott, K. C., Yebra, M., Mielgo, A., Lowy, A. M., Husain, H., Cascone, T., Diao, L., Wang, J., Wistuba, I. I., Heymach, J. V., Lippman, S. M., Desgrosellier, J. S., Anand, S., Weis, S. M., & Cheresh, D. A.
Affiliations: University of California San Diego (US)
The University of Texas MD Anderson Cancer Center (US)
Corresponding author: Cheresh, David A.
ORCID: Seguin, Laetitia
Kato, Shumei
Franovic, Aleksandra
Camargo, M. Fernanda
Mielgo, Ainhoa
Lowy, Andrew M.
Husain, Hatim
Cascone, Tina
Diao, Lixia
Wang, Jing
Wistuba, Ignacio I.
Heymach, John V.
Lippman, Scott M.
Desgrosellier, Jay S.
Anand, Sudarshan
Weis, Sara M.
Cheresh, David A.
Venue: Nature Cell Biology
Publisher: Springer Science and Business Media LLC
Published: 2014-04-20
Volume: 16
Issue: 5
Pages: 457-468
ISSN: 1465-7392 (ISSN-L)
1476-4679
DOI: 10.1038/ncb2953
PMC: PMC4105198
OpenAlex: W2029572050
Cited by: 374
References: 59
Citations by year: 2026: 11 · 2025: 21 · 2024: 22 · 2023: 32 · 2022: 27 · 2021: 36 · 2020: 35 · 2019: 41 · 2018: 28 · 2017: 33 · 2016: 40 · 2015: 34 · 2014: 14
FWCI: 19.48
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Cell Biology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: Association pour la Recherche sur le Cancer
National Institutes of Health
U.S. Public Health Service (R3750286)
National Heart, Lung, and Blood Institute (HL 57900, R00HL112962, P01HL057900)
National Cancer Institute (CA-45726, R01CA045726, CA155620, R01CA155620, R37CA050286, R01CA168692, CA168692, P30CA023100, T32CA121938, P30CA016672)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords: integrin αvβ3, KRAS, RalB, erlotinib resistance, cancer stemness, cancer stem cells, NF-κB activation, TBK1, bortezomib, anchorage-independent growth, self-renewal, tumor initiation, lung cancer, breast cancer, pancreatic cancer
MeSH terms: Erlotinib Hydrochloride, Animals, Female, Humans, Lung Neoplasms, Mice, Nude, Phenotype, Proto-Oncogene Proteins, Quinazolines, Time Factors, Transfection, Tumor Cells, Cultured, Neoplastic Stem Cells, Signal Transduction, Randomized Controlled Trials as Topic, Proto-Oncogene Proteins p21(ras), Mice, SCID, Mice, Inbred NOD, Clinical Trials, Phase II as Topic, Protein Serine-Threonine Kinases, ras Proteins, Spheroids, Cellular, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-rel, ral GTP-Binding Proteins, Xenograft Model Antitumor Assays, RNA Interference, Integrin alphaVbeta3, Integrin beta3, Cell Line, Tumor, Tumor Burden, Protein Kinase Inhibitors, Cell Proliferation, Mice, Molecular Targeted Therapy, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks